Posts Tagged ‘pharmaceutical industry’

Psychiatry’s New Billing Bible, The DSM: A Goldmine of Mental Disorders for Pharma

Wednesday, February 10th, 2010

By CCHR Int

The American Psychiatric Association’s release of the proposed fifth revision of its billing bible, the Diagnostic and Statistical Manual of Mental Disorders (DSM) fuels University of California’s  Dr. Irwin Savodnik’s statement, “The very vocabulary of psychiatry is now defined at all levels by the pharmaceutical industry.”

Take a look at some of psychiatry’s proposed mental disorders for their new manual and you can bet Pharma already has clinical drug trials in the works for such ludicrous mental “illnesses” as: Compulsive Shopping disorder, Skin Picking Disorder, Hoarding Disorder, Olfactory Reference Syndrome (smelling things not really there), Gender Identity Disorder, Impulse-Control Disorders Not Elsewhere Classified, and then there’s the redefinition of losing your cool: Temper Dysregulation (mood swings) Disorder with Dysphoria (abnormal discontent).  Add to that one of psychiatry’s latest drug sale boosters, Restless Leg Syndrome, newly added to the DSM.

The real danger of any revision of DSM, despite medicalizing all of life’s problems or idiosyncratic behaviors into a mental “disease” is that it is the primary feeder line for psychiatric drug sales.  Psychiatry’s 300% increase of mental disorders in the DSM over five decades has already generated billions of dollars in government funding—largely covering drug treatment.  Since DSM-IV in 1994, there has been a 256% increase in antipsychotics and antidepressants drug sales.  The diagnosis of so-called bipolar disorder has increased 4000%, with 2.5 million kids now on antipsychotic drugs that can cause life-threatening side effects including diabetes, fatal blood clots, cardiac arrest, suicidal thoughts and violence.

Despite major controversy and Senate investigations into psychiatry’s conflicts of interest (psychiatrists get more money from Pharma than any other medical specialty), psychiatrists participating in the DSM-V revision still have direct ties to Pharma: 18 of the 20 members overseeing the revision for treating just three “mental disorders” have financial ties to drug companies, with drug treatment for these disorders alone generating $25 billion a year in pharmaceutical sales.  Since 2008, the APA has been under U.S. Senate Finance Committee investigation for its conflicts of interest with the pharmaceutical industry, from which it derives a third of its annual income.

In the earlier revision, the Committee was rife with psychiatrists with undisclosed financial interests with pharmaceutical companies, with sales of drugs for conditions voted into the DSM resulting in more than $80 billion in revenue worldwide.

As the late Dr. Sydney Walker III, a neurologist and psychiatrist, wrote: “Drug company money influences every aspect of modern-day psychiatry. The American Psychiatric Association is literally built on a foundation of drug money…In return, the APA bends over backward to help drug companies promote their products.”[1] This habit looks more like one of the compulsions the APA tries so hard to foist off on others in its proposed new cookbook of mental disorders: DSM-V.

Further, the APA advises members about DSM-V: “when considering whether to add a mental/psychiatric condition to the nomenclature, or delete a mental/psychiatric condition from the nomenclature, potential benefits…should outweigh potential harms….” Emphasis added for a reason: delete a mental disorder?   If psychiatrists can simply delete  a mental disorder, does that mean that all the people previously diagnosed with the “illness” who were drugged and harmed, get to sue the APA for being fraudulently diagnosed?

As Lawrence Stevens, former Assistant District Attorney in California, stated in response to the APA “deleting” homosexuality as a mental disorder in 1973 (prompted only by activists protesting it): “If mental illness were really an illness in the same sense that physical illnesses are illnesses, the idea of deleting homosexuality or anything else from the categories of illness by having a vote would be as absurd as a group of physicians voting to delete cancer or measles from the concept of disease.”[2]

For more information on the DSM click here.


[1] Sydney Walker, III, M.D., A Dose of Sanity, (John Wiley & Sons, Inc, New York, 1996), p. 229.

[2] Lawrence Stevens, J.D., “Does Mental Illness Exist?,” undated article, Internet URL: http://www.mentalhealthfacts.com/antipsychiatry/exist.htm, accessed: 9 Jan. 2001.

« Return to news items


  • Share/Bookmark

NAMI – the ‘patients rights’ group which is really funded by & a major lobbying arm of Psycho/Pharma – is on the defensive

Tuesday, December 15th, 2009

Ed Silverman
Pharmalot
December 15, 2009

The National Alliance on Mental Illness is on the defensive. After reports that most donations made to the big advocacy group came from drug makers in recent years, NAMI agreed to disclose its funding sources. The disclosure, however, came after protracted criticism of NAMI for coordinating lobbying efforts with drug makers and pushing legislation that also benefits the pharma industry.

The embarassing episode prompted NAMI’s executive director, Michael Fitzpatrick, to acknowledge industry donations were excessive and that things would change. Meanwhile, board member Richard Lamb resigned over the issue, complaining little was changing, saying NAMI’s dependence on drugmakers made some actions impossible, such as warning against the use of some mental health drugs with life-threatening side effects.

Read entire article: http://www.pharmalot.com/2009/12/nami-runs-a-survey-on-pharma-funding/?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+Pharmalot+(Pharmalot)

« Return to news items


  • Share/Bookmark

Depression as a mass marketing campaign: Drug companies profit as antidepressant prescriptions increase

Friday, November 27th, 2009

Keith McLaughlin
The Argosy.ca
November 26, 2009

Since the emergence of antidepressant drugs in the early 1980s, more and more cases of depression are being reported. According to Dr. Brad Hagen, a clinical psychologist and faculty member at the University of Lethbridge, the reason for the skyrocketing rates of depression are a matter of heated debate.
“Depending on how you look at it, depression either started becoming more common or recognized, or it became marketed,” says Hagen.
In the 1950s, reported cases of depression were practically unheard of, but now the World Health Organization warns it could become the second leading cause of disability in the world by 2020.
Most persons with depression are treated by antidepressants, even though counseling – which can be significantly more expensive and time-consuming – has demonstrated equal effectiveness in offsetting feelings of depression. In the U.S, 87 per cent of physician visits for depression result in antidepressants being prescribed.
In 2007, sales of antidepressants topped $11.9 billion in the U.S.
Some in the medical community wonder if the spike in diagnosed depression cases over the last twenty years is exaggerated.
“Some question whether it’s an overinflated number because essentially there’s people that benefit from so many people being diagnosed,” says Hagen.

Read entire article: http://www.argosy.ca/view.php?aid=41974

« Return to news items


  • Share/Bookmark

Renowned researcher says public is mislead about antidepressants: they simply put people into drug induced states

Monday, November 23rd, 2009

David Gutierrez
NaturalNews.com
November 23, 2009

Contrary to the impression promoted by the psychiatric and drug industries, psychiatric drugs do not work by correcting a chemical imbalance in the brain, Joanna Moncrieff of University College London wrote recently in an opinion piece for the BBC. Instead, such drugs merely put people into “drug-induced states” that make it harder for them to experience the symptoms of their illness.

“Magazines, newspapers, patients’ organizations and Internet sites have all publicized the idea that conditions like depression, anxiety, schizophrenia and bipolar disorder can be treated by drugs that help to rectify an underlying brain problem … just like a diabetic needs to take insulin,” Moncrieff writes. “The trouble is, there is little justification for this view.”

Moncrieff notes that prior to the 1950s, mental health workers largely saw antidepressants as psychoactive drugs, primarily sedatives, that eased the symptoms of depression without addressing the underlying cause – much as over-the-counter cold drugs may stop a runny nose without affecting the cold virus. This view was eventually replaced by the idea that depression, schizophrenia, anxiety and other mental health conditions result from chemical imbalances in the brain, imbalances that can be corrected by the right “magic bullet.”

Read entire article: http://www.naturalnews.com/027555_antidepressants_chemical_imbalances.html

« Return to news items


  • Share/Bookmark

U.S. Sen Grassley-Demanding transparency for Pharma funds paid to doctors, researchers, patient ‘advocacy’ groups

Thursday, November 19th, 2009

IowaPolitics.com
November 19, 2009

WASHINGTON — Senator Chuck Grassley has asked leading medical schools to describe their policies on ghostwriting as part of his continuing effort to shed light on financial ties between the pharmaceutical industry and medical professionals.

“I’m interested in transparency, and academic institutions play an important role in establishing adequate and meaningful disclosure. Letting the sun shine in and making information public is basic to building people’s confidence in medical research and the practice of medicine,” Grassley said.

Last July, Grassley wrote to eight leading medical journals to ask the same kinds of questions he’s presented to the medical schools. Prior to that, he asked two major drug companies about allegations that they hired ghostwriters to draft articles promoting company products and seek academics to sign on as primary authors.

Grassley also has conducted oversight and sought disclosure with physicians, continuing medical education and the patient advocacy community. He has worked to expose cases where there was vast disparity between drug-company payments received and reported by leading medical researchers. The National Institutes of Health is working on new disclosure guidelines for federal grant recipients in response to Grassley’s work.

In January, Grassley and Senator Herb Kohl introduced, for the second time, the Physician Payments Sunshine Act. The legislation would require annual public reporting by drug, device and biologic manufacturers of payments made to physicians nationwide. It was included in the health care reform bill passed in October by the Senate Committee on Finance.

Read entire article: http://www.iowapolitics.com/index.iml?Article=177376

« Return to news items


  • Share/Bookmark

70% of psychiatrists in charge of adding new mental disorders to psych billing bible (DSM) have conflicts/ties to Pharma

Wednesday, November 18th, 2009

Roger Collier
Canadian Medical Association Journal
November 17, 2009

Former editors of the Diagnostic and Statistical Manual of Mental Disorders (DSM) have publicly declared their concerns that the ongoing revision process of the influential publication has been cloaked in secrecy. In recent months, debate about the confidentiality agreement that contributors must now sign has been playing out in the pages of the Psychiatric Times. Dr. Allen Frances, editor of DSM-IV, has written several editorials slamming the DSM-V task force for their lack of transparency.

The “real problem now is the almost complete lack of openness about [DSM-V] methods, progress, timelines, and products,” Frances writes in an email.

Dr. Robert Spitzer, editor of DSM-III, has expressed a similar opinion. In 2008, he wrote an open letter criticizing the confidentiality agreement (Psychiatr News 2008; 43:26). In the letter, Spitzer says that he requested the minutes of a DSM-V meeting but was refused. The confidentiality mandate, he wrote, would prohibit the free exchange of information between the DSM task force and outside experts that is essential to effectively revising the manual.

Read entire article: http://www.cmaj.ca/earlyreleases/17nov09-dsm-revision-surrounded-by-controversy.shtml

« Return to news items


  • Share/Bookmark

“Was Fort Hood Killer On Psychotropic Drugs?” – Media fails to ask if Hasan was on SSRI’s

Friday, November 6th, 2009

Paul Joseph Watson
Alex Jones’ Prison Planet.com
November 6, 2009

Despite the fact that Fort Hood gunman Nidal Malik Hasan was a psychiatrist, the media has failed to even raise the question of whether he was taking psychotropic drugs before he gunned down over a dozen of his colleagues during yesterday’s tragic rampage, a hefty indictment of how the establishment rushes to blame politics, religion, gun rights, or any other factor for mass shootings in order to hide the direct link between such massacres and the use of anti-depressant drugs.

It has been confirmed that Hasan was an Army psychiatrist at Fort Hood. Psychiatrists have a history of “self-medication” because of the easy access they have to psychotropic drugs.

In almost every major mass shooting over the past two decades, since anti-depressant drugs became popular, the killer has been on SSRI’s – serotonin reuptake inhibitors.

The establishment media, allied closely as it is with the pharmaceutical industry, uniformly fails to stress this common factor, preferring instead to blame shootings on gun rights or, as in the case of Hasan, political motives.

Read entire article: http://www.prisonplanet.com/was-fort-hood-killer-on-psychotropic-drugs.html

« Return to news items


  • Share/Bookmark

Dr. Peter Breggin: Antipsychotic Drugs, Their Harmful Effects, and the Limits of Tort Reform

Monday, November 2nd, 2009

Dr. Peter Breggin
The Huffington Post
October 31, 2009

There are many problems within our legal system that could benefit from reform. But within the area in which I have great experience as a psychiatric expert, so-called tort reform has already gone too far. It is already too difficult for injured patients or their surviving families to bring malpractice suits against physicians and health facilities, and product liability suits against drug companies, even when their cases have great merit. I believe in private health care and I believe in the free market, but liberty requires checks and balances. The right to sue medical practitioners and pharmaceutical companies provides a necessary control in our free market system, as well as a means for individuals to seek compensation and justice.

Harm Caused by Antipsychotic Drugs

For illustrative purposes, I’ll focus on the newer antipsychotic drugs, the so-called atypicals, including Zyprexa, Risperdal, Geodon, Seroquel, and Abilify. These drugs produce horrendous adverse effects that often lead the victims or their surviving families to consider bringing lawsuits against doctors, health care facilities, or drug companies.

First, the antipsychotic drugs produce tardive dyskinesia. Tardive dyskinesia involves drug-induced abnormal movements that commonly disfigure patients and in some cases result in lifelong pain and total disability.

Read entire article: http://www.huffingtonpost.com/dr-peter-breggin/antipsychotic-drugs-their_b_341108.html

« Return to news items


  • Share/Bookmark

Irish Times: “Tinseltown gets the big picture on psychiatry – it sucks”

Sunday, October 25th, 2009

Irish Times.com
October 24, 2009

LOS ANGELES LETTER: “PSYCHIATRY: AN Industry of Death” is the name of a museum on Sunset Boulevard. For several hours you can roam a dungeon-style premises that delivers a clear and sustained message: psychiatry sucks, writes JOHN FLEMING.

As the LA palm trees outside overstretch themselves into the blue sky and six lanes of flash cars and pick-up trucks roar past, you are sealed into a theatrical world of condemnation.

In a stage set of straitjackets, restraining tables and human cattle-prods, a versioned world of psychiatry’s lobotomies, ECT and involuntary commitments is vividly dramatised.

Fourteen of Hollywood’s most secret short films and hundreds of dark exhibits sketch a shameful history of the profession, blaming it for racism, the Holocaust, botched psychosurgery and a world dependent on the pharmaceutical industry.

Read entire article: http://www.irishtimes.com/newspaper/world/2009/1024/1224257390508.html

« Return to news items


  • Share/Bookmark

Sen. Grassley’s bill requires disclosure of Pharma $ to doctors, ghost writers & “patient advocacy” groups like NAMI

Friday, October 23rd, 2009

IowaPolitics.com
October 23, 2009

WASHINGTON — Senator Chuck Grassley is continuing his campaign to establish transparency with the financial relationships between drug companies and medical professionals.

Grassley has conducted oversight and sought disclosure with physicians, especially those involved in influential taxpayer-sponsored medical research; medical journals containing ghostwritten articles; medical colleges; continuing medical education; and the patient advocacy community.

This week, the senator released a letter seeking information from state-level chapters of the National Alliance on Mental Illness. The inquiry follows one Grassley made earlier this year asking NAMI and other patient advocacy groups and medical professional societies for information about financial relationships with drug companies and medical device manufacturers. The letter is posted with this news release at http://grassley.senate.gov and http://finance.senate.gov.

“Public trust and public dollars are at stake,” Grassley said. “People rely on medical advice and taxpayers spend billions of dollars on prescription drugs and devices through Medicare and Medicaid. Public confidence could be greatly improved if financial relationships were disclosed. My legislative effort is a common-sense reform that would require the pharmaceutical and device industry to report the money it gives to doctors.”

Read entire article: http://www.iowapolitics.com/index.iml?Article=174518

« Return to news items


  • Share/Bookmark